Best of 2025: Streamlined workflows and novel therapies in ocular surface disease
Our most-read dry eye disease coverage of 2025 reflects a growing emphasis on efficiency, innovation, and practical application in everyday practice. From stepwise frameworks designed to simplify visits and improve adherence to expert discussions on neuromodulator therapy and real-world clinical pearls, these highlights showcase how clinicians are refining dry eye management to deliver more consistent, patient-centered care.
Kickstart dry eye disease management in 3 streamlined steps
In this clinician perspective, Blair Lonsberry, OD, outlines a practical, stepwise approach to dry eye disease that starts with foundational care, establishes a clear baseline, and selectively “kickstarts” advanced therapies only when needed—helping streamline visits, improve patient adherence, and achieve lasting ocular surface stability.
Read the full article here.
Neuromodulator therapy for dry eye disease: an exciting new option
In part 3 of a 5-part video series, Marjan Farid, MD, of the University of California, Irvine; Karolinne Rocha, MD, PhD, of the Medical University of South Carolina; Nathan Lighthizer, OD, of the Northeastern State University Oklahoma College of Optometry; and Cory Lappin, OD, the Dry Center of Ohio, discuss a new treatment option for dry eye disease, TRYPTYR (acoltremon), which targets the basal tear production pathway.
Watch the full video here.
Panel takeaways: pearls of practice for dry eye disease
In the final segment of a 5-part video series, Marjan Farid, MD, of the University of California, Irvine; Karolinne Rocha, MD, PhD, of the Medical University of South Carolina; Nathan Lighthizer, OD, of the Northeastern State University Oklahoma College of Optometry; and Cory Lappin, OD, the Dry Center of Ohio, give important practice takeaways for clinicians who treat patients with dry eye disease.
Watch the full video here.
Related Content
